Opioid Addiction Treatment

The Evidence Base for Opioid Addiction Treatment

Opioid use disorder (OUD) is one of the most extensively researched addiction conditions in medicine, and the evidence for effective treatment is robust. The World Health Organization, the National Institute on Drug Abuse (NIDA), and the American Society of Addiction Medicine (ASAM) all endorse a treatment model that combines pharmacotherapy with behavioural interventions delivered in a structured clinical setting.

Research consistently demonstrates that medication-assisted treatment (MAT) produces superior outcomes across every measurable domain: treatment retention, reduction in illicit opioid use, reduction in overdose deaths, decrease in criminal activity, improvement in social functioning, and reduction in infectious disease transmission. A landmark Cochrane review found that buprenorphine maintenance therapy retained patients in treatment at roughly twice the rate of placebo, while methadone maintenance showed even higher retention rates for individuals with severe dependence.

At Phuket Island Rehab, the treatment programme is built on this evidence base and adapted to the residential setting. The geographic separation from home environments, combined with 24-hour clinical support, creates conditions that maximise treatment engagement during the critical early recovery period when relapse risk is highest.

Phase One: Medically Supervised Detoxification

The first phase of opioid addiction treatment is medically supervised detoxification, which safely manages the acute withdrawal syndrome that occurs when opioid use is discontinued. Opioid withdrawal, while rarely life-threatening in isolation, produces severe physical discomfort that drives the vast majority of unsupervised quit attempts back to use within 72 hours.

At Phuket Island Rehab, detoxification is managed using a carefully titrated buprenorphine induction protocol. Buprenorphine, a partial mu-opioid agonist, occupies opioid receptors sufficiently to suppress withdrawal symptoms and cravings without producing the full euphoric effect of drugs like heroin or oxycodone. The induction process requires precise timing: buprenorphine must be initiated after the onset of early withdrawal symptoms to avoid precipitated withdrawal, a paradoxical worsening of symptoms caused by buprenorphine displacing full agonists from opioid receptors.

Adjunctive medications target specific withdrawal symptoms. Clonidine, an alpha-2 adrenergic agonist, reduces autonomic hyperactivity (sweating, tachycardia, hypertension). Ondansetron or metoclopramide manages nausea and vomiting. Loperamide addresses diarrhoea. Trazodone or melatonin supports sleep. Ibuprofen or paracetamol provides relief from musculoskeletal pain. This multimodal approach reduces withdrawal severity by 60 to 70 percent compared to unmedicated detox.

Phase Two: Residential Therapeutic Programme

Once medically stabilised, clients at Phuket Island Rehab transition into the core residential therapeutic programme. This phase addresses the psychological, behavioural, and relational dimensions of opioid addiction through a structured daily schedule that includes individual therapy, group therapy, psychoeducation, experiential activities, and wellness programming.

Cognitive-behavioural therapy (CBT) is the primary psychotherapeutic modality. CBT helps clients identify the automatic thoughts, beliefs, and cognitive distortions that drive opioid seeking. Through structured exercises, clients learn to recognise high-risk situations, challenge maladaptive thought patterns (such as “I cannot cope with stress without opioids”), and develop alternative coping strategies. Meta-analyses consistently rank CBT among the most effective psychosocial interventions for substance use disorders.

Dialectical behaviour therapy (DBT) provides skills training in four domains: mindfulness, distress tolerance, emotional regulation, and interpersonal effectiveness. These skills are particularly valuable for opioid-dependent individuals who have relied on the drug to manage emotional pain, given that many OUD patients report using opioids primarily to numb psychological distress rather than to seek euphoria.

Trauma-focused therapy, including Eye Movement Desensitisation and Reprocessing (EMDR), addresses the high prevalence of traumatic experiences among individuals with OUD. Research indicates that 50 to 70 percent of people seeking treatment for opioid addiction meet criteria for post-traumatic stress disorder. Processing unresolved trauma reduces a primary driver of self-medication and relapse.

Medication-Assisted Treatment Options

Three medications are approved for the treatment of opioid use disorder, each working through a different pharmacological mechanism. The choice of medication depends on the severity of dependence, the individual’s treatment history, co-occurring medical conditions, and personal preference.

Buprenorphine is the most widely used MAT medication in residential settings. As a partial agonist, it provides sufficient receptor activation to prevent withdrawal and reduce cravings while having a ceiling effect that limits respiratory depression risk. Buprenorphine can be prescribed by certified physicians in various formulations including sublingual tablets, sublingual films, and long-acting injectable depots.

Methadone, a full mu-opioid agonist, is reserved for individuals with severe dependence who have not responded adequately to buprenorphine. Methadone requires daily supervised dosing in most jurisdictions and provides the highest treatment retention rates of any MAT medication. However, its full agonist properties carry a higher overdose risk if doses are not carefully managed.

Naltrexone, available as a daily oral tablet or monthly injectable (Vivitrol), is an opioid antagonist that completely blocks opioid effects. It is most appropriate for highly motivated individuals who have completed detoxification and wish to maintain abstinence. The injectable formulation eliminates adherence concerns associated with daily oral dosing.

Treating Co-Occurring Disorders

Effective opioid addiction treatment must address co-occurring mental health conditions, which are present in an estimated 60 to 80 percent of individuals with OUD. The most common co-occurring disorders include major depressive disorder, generalised anxiety disorder, post-traumatic stress disorder, bipolar disorder, and personality disorders (particularly borderline and antisocial subtypes).

Integrated treatment, where substance use and mental health disorders are treated simultaneously by the same clinical team, produces significantly better outcomes than sequential or parallel treatment models. At Phuket Island Rehab, psychiatric evaluation occurs during the intake assessment, and medication management for co-occurring conditions (such as SSRIs for depression or mood stabilisers for bipolar disorder) is initiated alongside addiction-specific treatment.

Chronic pain is another critical co-occurring condition in opioid-dependent populations, given that many individuals initially developed OUD through prescribed pain management. The treatment team develops a multimodal pain management strategy that may include non-opioid analgesics, physical therapy, mindfulness-based pain reduction, and careful evaluation of whether continued opioid therapy (via buprenorphine, which has analgesic properties) is clinically appropriate.

Aftercare and Long-Term Recovery Support

The transition from residential treatment back to daily life is the highest-risk period for relapse. Phuket Island Rehab mitigates this risk through a structured twelve-month aftercare programme that begins during the residential phase with discharge planning and continues through regular telehealth sessions, medication management support, and connection with recovery communities in the client’s home country.

Aftercare includes weekly or biweekly video check-ins with the primary therapist during the first three months, transitioning to monthly sessions as stability increases. Clients receive a personalised relapse prevention plan that maps their specific triggers, early warning signs, and rehearsed coping responses. For clients on MAT, coordination with a local prescriber ensures uninterrupted medication access after discharge.

Frequently Asked Questions

How long does opioid addiction treatment take?

A comprehensive treatment episode typically includes 7 to 14 days of medically supervised detoxification followed by 28 to 90 days of residential therapy. Individuals with severe OUD or co-occurring disorders often benefit from extended stays of 90 to 180 days. Aftercare continues for twelve months following discharge. Research consistently shows that longer treatment durations correlate with better long-term outcomes.

Will I need to take medication long-term?

The duration of medication-assisted treatment is individualised. Some individuals taper off buprenorphine or naltrexone after residential treatment, while others benefit from maintenance therapy lasting months or years. The clinical team at Phuket Island Rehab works with each client to develop a medication plan based on their severity of dependence, relapse history, and personal goals. There is no predetermined timeline, and the decision is always clinically guided.

What therapies are used for opioid addiction at Phuket Island Rehab?

The core therapeutic modalities include cognitive-behavioural therapy (CBT), dialectical behaviour therapy (DBT), motivational interviewing, trauma-focused EMDR, mindfulness-based relapse prevention, and group therapy. Each client receives an individualised treatment plan that emphasises the modalities most relevant to their specific presentation and needs.

Can opioid addiction treatment address chronic pain at the same time?

Yes. Chronic pain is one of the most common co-occurring conditions in opioid use disorder. The treatment team develops a multimodal pain management strategy that may include buprenorphine (which has analgesic properties), non-opioid medications, physical rehabilitation, and psychological pain management techniques such as mindfulness-based stress reduction.

What happens if I relapse after treatment?

Relapse is not a sign of treatment failure. It is a recognised part of the recovery process for a chronic condition. Phuket Island Rehab’s aftercare programme is designed to identify relapse warning signs early and provide immediate intervention. If a relapse occurs, the clinical team can adjust the treatment plan, reinstate or modify medication, and provide additional therapeutic support.

Clinical Reviewer: Dr. Ponlawat Pitsuwan, Physician | Publisher: Phuket Island Rehab | Last Updated: April 2026 | Clinical Entities: Opioid use disorder, medication-assisted treatment, buprenorphine, naltrexone, methadone, cognitive-behavioural therapy, dialectical behaviour therapy, EMDR, ASAM, NIDA, DSM-5